AbbVie Inc. $ABBV Shares Purchased by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 2.7% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 150,563 shares of the company’s stock after purchasing an additional 3,991 shares during the quarter. AbbVie accounts for approximately 1.0% of Dana Investment Advisors Inc.’s investment portfolio, making the stock its 14th largest holding. Dana Investment Advisors Inc.’s holdings in AbbVie were worth $34,861,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie during the 2nd quarter valued at $26,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie in the 2nd quarter valued at $28,000. Redmont Wealth Advisors LLC purchased a new position in AbbVie in the third quarter valued at about $41,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie during the second quarter worth about $36,000. Finally, Delos Wealth Advisors LLC purchased a new stake in shares of AbbVie in the second quarter worth about $39,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. HSBC raised AbbVie from a “hold” rating to a “buy” rating and boosted their price target for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research report on Tuesday, January 20th. Piper Sandler upped their target price on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday, November 3rd. Finally, UBS Group decreased their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $252.79.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Announced a $380 million build-out of two active pharmaceutical ingredient (API) facilities at its North Chicago campus to support next‑generation neuroscience and obesity medicines; expands domestic capacity and supports long‑term product supply and commercialization. AbbVie to Invest $380 Million in North Chicago
• Positive Sentiment: U.S. FDA approved the combination of Venclexta and acalabrutinib for previously untreated chronic lymphocytic leukemia (CLL), which could expand label use and drive additional oncology revenue. FDA approves Venclexta + acalabrutinib for CLL
• Positive Sentiment: Advanced ABBV‑8736 into a Phase 1 trial comparing injection routes (PK-focused) — early clinical progress that de‑risks part of the pipeline, though commercial impact is longer term and uncertain. AbbVie Advances ABBV-8736 With New Trial
• Positive Sentiment: Erste Group raised its FY2026 EPS forecast for AbbVie, lifting expectations for near‑term earnings which can support valuation and investor sentiment. AbbVie FY2026 EPS Forecast Boosted
• Neutral Sentiment: Industry talent movement: IDEAYA named a former AbbVie VP as Chief Development Officer — notable for personnel flow but unlikely to move AbbVie’s near‑term fundamentals. IDEAYA appoints ex‑AbbVie exec
• Negative Sentiment: Analyst commentary highlights a growth showdown with Johnson & Johnson and ongoing patent/competition risks — a reminder that AbbVie faces external pressures that could cap upside if key franchises weaken. Johnson & Johnson vs. AbbVie: A Growth Showdown

AbbVie Price Performance

Shares of ABBV stock opened at $229.19 on Tuesday. The firm has a fifty day moving average of $224.07 and a two-hundred day moving average of $222.45. The firm has a market cap of $405.07 billion, a P/E ratio of 97.11, a P/E/G ratio of 0.78 and a beta of 0.35. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.